Kornimate/medical-research-clean huggingface dataset:
effect of graminex on infertility related to male accessory glands inflammation

Conditions: Male Infertility; Prostatitis

Summary: male accessory glands inflammations (magi) include inflammatory diseases involving seminal vescicles and the prostate. patients suffering from them present an impaired fertility because of seminal duct obstruction and alterations of the rheologic and functional parameters of semen, induced by direct microbiological action as well as inflammatory and oxidative damage. inflammation in seminal plasma can be detected and measured by dosing of inflammatory molecules such as supar and st2. treatment of magis include specific antibiotic therapy in addition to use of anti-inflammatory nutraceutics. deprox hp is a nutraceutic containing graminextm, a compound made of pollen extracts of rye, mais and timothy. to investigate its efficacy, we evalued seminal parameters, inflammatory and oxidative molecules in seminal plasma and clinical and ultrasonographic features of male accessory glands before and after 3 months of treatment in 20 patients taking deprox hp and 20 patients undergoing treatment with palmitoilethanolammide, bromelin and horse chestnut extract.


Eligibility criteria:
inclusion criteria: * male patients with a diagnosis of magi based on clinical and/or ultrasonographic criteria. exclusion criteria: * history of cryptorchidism, orchitis, testicular torsion or trauma, * hypogonadism, * occupational chemical exposure, * y chromosome microdeletions, karyotype abnormalities and cystic fibrosis transmembrane conductance regulator (cftr) mutations, * ultrasound testicular volume \<12 ml, * fsh \>8 mui/l, * fever or drug use within 3 months prior to the enrollment in this study * azoospermia.
pilot study to assess telemonitoring of gleevec (imatinib mesylate) or tasigna (niltinib) therapy

Conditions: Chronic Phase CML

Summary: this study is being conducted in a population of patients with chronic phase chronic myeloid leukemia (cml) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.

this is a randomized, controlled pilot study to introduce emedonline telemonitoring technology to cml patients taking gleevec or tasigna. emedonline will be used to automatically collect time-dose specific medication data for individual patients, including dosing times, missed doses, adverse events and e-diary data. all data will be available to research staff for remote review via web interface. adverse events and non-adherence will prompt interventions including supportive care counseling.

Eligibility criteria:
inclusion criteria: * patients 18 years of age or older. * pathologically documented diagnosis of chronic phase cml (ph+) in whom treating physician has determined that treatment with imatinib or nilotinib is appropriate * patients currently receiving gleevec (imatinib) 300-600 mg daily or tasigna (nilotinib) 300-400 mg twice daily * known performance status 0,1 or 2 (ecog) * known adequate end organ function, defined as: total bilirubin \ 1.5 platlets \> 100,000 * patient is willing and able to use a cell phone * written, voluntary informed consent exclusion criteria: * patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent

Keywords: chronic myeloid leukemia
lupus genetics studies

Conditions: Systemic Lupus Erythematosus

Summary: the lupus genetics studies and lupus family registry \& repository are working to find the genes that reveal the causes of systemic lupus erythematosus (sle, or lupus). the study is enrolling families of all ethnic backgrounds from the united states, canada, puerto rico, and the virgin islands that have one or more living members diagnosed with sle.

sle is an often crippling and potentially fatal autoimmune disease that is nine times more prevalent in women than in men, and four times more likely to affect african american females than caucasian females. it is suspected that a genetic predisposition along with environmental factors contribute to the clinical manifestation of sle. the lupus genetics studies consist of several familial sle studies, including the lupus family registry \& repository (lfrr, formerly known as the lupus multiplex registry \& repository, or lmrr). the lupus studies enroll families of all ethnicities with one or more members diagnosed with systemic lupus to determine what genes contribute to the development of the disease. additionally, the lupus family registry \& repository is the largest repository of its kind in north america. in addition to the research done on site, the repository serves as a national resource for scientists interested in conducting research on sle and families either simplex or multiplex for lupus. data, serum samples, and dna samples are available to researchers. by collecting families in which two or more living individuals have been diagnosed with sle, the study is utilizing the genetic link between the affected family members to discover disease-associated genes. records will be requested from the patients' treating physicians to document various lupus symptoms and related problems. one-time blood samples will be collected from the patients as well as from certain family members and an unrelated volunteer. there is no cost to participate and the study pays for sample draws and shipping.

Eligibility criteria:
inclusion criteria: * families in which one or more living members have been diagnosed with systemic lupus erythematosus

Keywords: lupus genetics
a study to evaluate the relative bioavailability of a fixed-dose combination tablet of vx-121/tezacaftor/deutivacaftor

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet (fdc) of vx-121/tezacaftor/deutivacaftor (vx-121/tez/d-iva).

this clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (that is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(a) of the public health service act and 42 cfr 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the public health service act or 42 cfr 11.24 and 11.44.).

Eligibility criteria:
key inclusion criteria: * body mass index (bmi) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), both inclusive * a total body weight greater than (\>)50 kg key exclusion criteria: * history of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug * any condition possibly affecting drug absorption * female participants who are pregnant, nursing, or planning to become pregnant during the study or 90 days after the last dose of the study drug * male participants with a female partner who is pregnant, nursing, or planning to become pregnant during the study * history of cardiovascular disease or central nervous system disease other protocol defined inclusion/exclusion criteria may apply.
effects of radiotherapy in borderline and malignant phyllodes tumors after r0 resection

Conditions: Radiotherapy, Adjuvant; Phyllodes Breast Tumor; Prognosis

Summary: breast phyllodes tumors (pt) are rare fibroepithelial neoplasms originating from stromal tissue and account for less than 1% of all breast tumors. the world health organization (who) classifies pt into benign, borderline, and malignant subtypes based on pathological features such as mitotic activity, cellular atypia, tumor margin invasion, and stromal composition 1. the presence of malignant heterologous elements characterizes the tumor as malignant 2. surgery is the primary treatment. however, even after r0 resection, borderline phyllodes tumors (bopt) and malignant phyllodes tumors (mpt) patients remain face a high risk of local recurrence, with rates of 15%-20% and 25%-30%, respectively. moreover, metastases occur almost merely in mpt, with a distant metastasis rate reaching 22%. adjuvant radiotherapy has attracted attention for its potential to improve local control and reduce recurrence, but the role after r0 resection in pt patients remains unclear. radiotherapy significantly reduces local recurrence rates in bopt and mpt but shows no substantial benefit in benign cases. however, a meta-analysis by yu et al. found that this effect is limited to mpt. additionally, the effect of radiotherapy on survival rates in pt remains controversial. most existing studies are retrospective and face limitations such as small sample sizes. the rarity of pt and conflicting evidence of impact of radiotherapy necessitate further study. while prospective trials are difficult due to limited cases, well-designed retrospective studies can offer valuable insights. in this study, the investigators also analyzed prognostic factors and identified subgroups to provide a clinical reference for the application of postoperative radiotherapy in bopt and mpt patients.


Eligibility criteria:
inclusion criteria: * patients who were initially diagnosed with bopt or mpt and underwent r0 resection surgery exclusion criteria: * patients who had their initial surgery at other hospitals without accurate baseline data * patients who received radiotherapy before surgery * those presenting with initial distant metastasis before treatment * patients lost to follow-up after treatment * patients with a history of or concurrent breast cancer or precancerous lesions in the ipsilateral breast or with breast cancer in the contralateral breast
collaborative quality improvement (c-qip) study

Conditions: Coronary Heart Disease; Ischemic Stroke; Heart Failure

Summary: the overarching goal of this study is to develop, implement, and evaluate the effect of a collaborative quality improvement (c-qip) intervention (consisting of non-physician health workers, text messages for a healthy lifestyle, and a clinical decision support system) on processes of care and clinical outcomes among individuals with previous cardiovascular disease in india.

specific objectives of this study are: 1. to describe current practices, context, challenges, and opportunities regarding chronic management of cardiovascular disease from the patient, caregiver, provider, and health administrator perspectives in india. 2. to assess the transferability of components of internationally successful multifaceted quality improvement strategies and chronic care models to the indian healthcare context. 3. to conduct a pilot study to assess the acceptability, feasibility, and implementation fidelity of the c-qip strategy among individuals with cardiovascular disease attending out-patient clinics in india. 4. among individuals with cardiovascular disease, evaluate the effect of c-qip strategy on processes of care and clinical outcomes, health-related quality of life, and costs at 1 year compared with usual care.

Eligibility criteria:
inclusion criteria: participants should be: * age ≥18 years, both sexes * confirmed diagnosis of cardiovascular disease (ischemic heart disease, stroke, or heart failure irrespective of ejection fraction) * able to provide written informed consent. exclusion criteria: * pregnant women * those with any serious or uncontrolled medical condition (e.g., cancer) that may restrict the patient to come for follow-up.
diagnostic breath analysis study to detect sepsis

Conditions: Puerperal: [Major Infection] or [Sepsis]

Summary: analysis of exhaled breath samples using a high-speed gas chromatography medical device will identify volatile organic compounds (voc) that are specifically associated with sirs and sepsis. primary outcome measures will include the assessment of the znose diagnostic breath analysis system, which includes high-speed gas chromatography, in the early detection of sirs and sepsis as compared with current sirs and sepsis evaluation methods.

exhaled breath samples were collected in a tedlar bag or with a proprietary collection tube. the collection devices are clean and intended for single-use. they are manufactured with approved medical grade materials. patients were asked to breath into a single-use, medical grade mouthpiece which is connected to the collection bag or tube. the design of the collection devices does not allow the patient to rebreathe the exhaled gas sample. patients enrolled in the clinical study were asked to breathe into the breath collection device for 2 to 4 breaths. breath collection is completely non-invasive. breath samples were held for 30 days and retested at the end of the 30 day period to determine if the voc profile has changed over time.

Eligibility criteria:
inclusion criteria: inclusion criteria 1. age 18 years of age or older 2. able to give written and dated informed consent prior to any study specific procedures. 3. able to follow instructions for specific breathing maneuvers. 4. able to breath into a medical grade tube, vial or bag. 5. initial assessment and screening indicates sirs or sepsis. exclusion criteria: exclusion criteria 1. cognitively impaired and unable to complete informed consent documents. 2. unable to follow instructions during testing. 3. severe dyspnea. 4. use of supplement oxygen which cannot be discontinued during testing. 5. unable to perform breathing maneuvers required to provide multiple breath samples. 6. swallowing disorders or chronic aspiration. 7. history of pneumothorax. 8. patients requiring mechanical ventilation 9. patients who are pregnant. 10. patients who have smoked cigarettes or cigars within 30 days prior to trial admission.
individual dietary counseling based on taste-tests in patients with hematological cancer in cytostatic therapy

Conditions: Hematological Malignancy

Summary: the purpose of the study is to investigate whether a simple taste-test will increase the intake of energy as part of the individual dietary counseling.

the investigators will investigate the tastes (umami, bitter, salty, sweet and sour) that the patients prefers in order to increase the energy intake and reduce the risk of weight loss and loss of fat-free mass for patients with hematological cancer. the study will be conducted as a single blinded randomized controlled trial. 40 patients will be recruited, and will be divided into two groups; the intervention group and the control group. the patients will not know which group they belong to.

Eligibility criteria:
inclusion criteria: * 18 years or older * able to understand the "participant information" paper * diagnosed with hematological cancer * must be undergoing chemotherapy (at least one treatment during the study) * outpatient * be able to take pictures of meals (and send to the sub-investigators) * be able to speak and read the danish language exclusion criteria: * pacemaker

Keywords: cancer hematological malignancy
assessment of the role of the growth hormone (gh) onthe intestinal triglyceride-rich-lipoproteins (trl) metabolism

Conditions: Atherosclerotic Cardiovascular Disease

Summary: atherosclerotic cardiovascular disease (ascd) is the first cause of morbidity and mortality in insulin resistant states. the typical dyslipidemia that is associated with insulin resistance, which includes a postprandial increase of triglyceride-rich lipoproteins (trl) with excess of intestinal triglyceride-rich-lipoprotein-apob-48 (trl-apob-48), is felt to play an important role in the accelerated ascd. recently, intestinal trl-apob-48 overproduction appeared as a newly recognized component of insulin resistance. there is only a limited amount of information in the literature regarding the factors and the mechanisms modulating the metabolism of intestinal trl-apob-48 in the setting of insulin resistance


Eligibility criteria:
inclusion criteria: male or feminine * age from 18 to 70 years * deficit in growth hormone informed by a peak lower than 10 mui / l in answer to a test of hypoglycemia (or another test of stimulation if the hypoglycemia insulinique is dissuaded) (cf. attached the rcp of various growth hormone used at the adult) * centre (treatments optimized previously will be maintained during all the duration of the study) thyréotrope, corticotrope and gonadotrope substituted well for at least 6 months * imc(cerebral-motor handicapped) \< 30 kg / m2 * fasting blood glucose \< 1,26 g/l * clearance of the creatinine \> 60 ml / min exclusion criteria: nobody particularly protected: incapable major and private person of freedom, person hospitalized for another pathology; · nobody mastering the reading of the french language * carrier patients of a tumor in service * pregnant woman
the effect of music on postoperative anxiety

Conditions: Anxiety Postoperative

Summary: in this study, it is planned to compare the effect of listening to the music preferred by the patient and classical music on postoperative anxiety.

preoperative anxiety can be detected via structured and standardized screening by the state-trait anxiety inventory (stai) i and ii. 225 patients scheduled for inguinal hernia surgery for any reason in the age range of 18-70 will be included in our study. preoperative stai i and ii score (anxiety questionnaire) will be applied to each patient. the patients will be divided into three groups as preoperative patient preferential music, classical music and not played. the patient favorite music track and singer without limiting the kind of music or classical music will be played through the headphones. the stai will be repeated at postoperative, the numeric rating scale (nrs) and patient satisfaction will be measured at postoperative.

Eligibility criteria:
inclusion criteria: * undergo inguinal hernia surgery under general anesthesia, * being the ability to speak, read and write the turkish language exclusion criteria: * poor vision * significant hearing loss * dementia * active opioid use * regular use of anxiolytics or discontinuation of them on the day of surgery * unwillingness to participate in the study * unwillingness to listening to music

Keywords: patient preferential music postoperative anxiety classical music
semi-barbed suture for pulmonary small nodules localization

Conditions: Suture; Nodule, Solitary Pulmonary; Video-Assisted Thoracoscopic Surgery

Summary: hookwire and microcoil are currently the most widely used localization instruments. although their success rate is relatively high in preoperative localization attempts, they may lead to consequences that negatively affect patient outcomes, such as pain because of the metal's hardness, localization failure due to wire detachment, and the presence of permanent traces of metal and foreign bodies . to overcome these disadvantages, we designed an absorbable semi-barbed suture to localize small intrapulmonary nodules (patent number: zl201821444387.x). the results of the previous animal experiments were satisfactory, and it is now necessary to recruit 10 patients for clinical trials.


Eligibility criteria:
inclusion criteria: 1. solid nodules with a diameter2cm and distance to visceral pleura 0.5cm； 2. ggn； 3. part-solid ggn, with a solid portion1cm and distance to the visceral pleura 1cm； 4. patients with nodules at a deep location, who underwent localization to facilitate localization in the resected specimen by a pathologist exclusion criteria: 1. the lesion site is not suitable for percutaneous lung puncture; 2. those who have pneumothorax and pleural effusion; 3. poor general condition, severe damage to cardiopulmonary function, cachexia, and inability to tolerate surgery; 4. those who refuse surgery; 5. those who did not sign the informed consent form.
efficacy and safety of oxantel pamoate in children infected with trichuris trichiura

Conditions: Trichuris Trichiura; Infection; Hookworm Infection; Ascaris Lumbricoides Infection

Summary: this study aims to provide evidence on the efficacy, safety and acceptability of the new, chewable formulation of oxantel pamoate administered as a single dose or multiple doses, compared to mebendazole in children infected with t. trichiura. this study will involve children aged 2-12 years, since an infection with t. trichiura occurs often in children.


Eligibility criteria:
inclusion criteria: * aged between 2 and 12 years. * written informed consent signed by parents/caregivers (signature or thumbprint) and, for children aged 6-12 years, written assent from the child. * agree to comply with study procedures, including provision of two stool samples at the baseline and at follow-up assessment 14-21 days after treatment, respectively. * at least two out of four kato-katz thick smears positive for t. trichiura at baseline. * willing to be examined by a study physician prior to treatment. exclusion criteria: * presence or signs of major systemic illness or abnormal physical findings at screening, e.g. severe anaemia (hb level \<80 g/l according to who) upon initial clinical assessment. * known allergy to study medication (i.e. oxantel pamoate, mebendazole or any of the excipients). * use of anthelminthic drugs within 4 weeks before or during study period. * being prescribed or taking concomitantly medication with known contraindication or drug interactions with the study medication. * actively participating in other clinical trials during the study. * pregnancy (female participants that report to have reached menarche
a randomised study evaluating diagnostics of pleural effusion among patients suspect of cancer.

Conditions: Pleural Effusion, Malignant; Pleural Effusion; Pleura; Exudate

Summary: pleural fluid can be caused by cancer. patients with repeated presentation of pleural fluid where initial diagnostic tests have been inconclusive are the focus of this trial. in this clinical trial patients are randomized into two groups and the efficacy of local anesthetic thoracoscopy (lat) is compared to an ultrasound guided biopsy of the outer lining of the lung. the aim is not only the diagnostic yield in diagnosing cancer, but also the procedures ability to diagnose specific cancer mutations and immune system markings. methods and objectives: patients with reoccuring one-sided pleural fluid, with a marked clinical risk of cancer based on findings in medical work-up, radiological scans, biochemistry and medical history and who are undiagnosed upon initial pleural fluid analysis are the target patients of the trial. patients are randomized into two groups to have undertaken either pleural biopsy at the optimal site for a repeat thoracentesis or lat. thus diagnostic yield for both fluid analysis and biopsy analysis will be compared to tissue samples taken with lat. we hypothesize that lat is superior both to pleural biopsy and repeat thoracentesis in providing diagnostic clarification and providing sufficient basis for treatment without further procedures resulting in less time consumption, cost and discomfort for the patient.


Eligibility criteria:
inclusion criteria: * age 18 years or older patients with single previous thoracentesis of a unilateral pleural exudate according to lights criteria without malignant cells. * lights criteria: pleural fluid protein/serum protein ratio greater than 0.5 pleural fluid ldh/serum ldh ratio greater than 0.6 pleural fluid ldh greater than two-thirds the upper limits of the laboratorys normal serum ldh * contrast enhanced ct of the chest and abdomen performed * clinical suspicion of cancer such as, but not limited to, weight loss, malaise, anemia * pet-ct results or former cancer diagnosis informed consent exclusion criteria: * bilateral pleural effusions * known cause of pleural effusion * likely non-malignant course of a unilateral pleura effusion such as (but not restricted to) pneumonia, trauma, pleuritis, heart failure * any contraindication to the study procedures

Keywords: pleural effusion malignant pleural effusion pleura diagnostics us-guided pleural biopsy local anesthetic thoracoscopy